EGFR and non-small cell lung carcinoma: For tyrosine kinase inhibitors (TKIs) [9], mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target: for example, the single amino acid mutation tyrosine/methionine (T790M) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs erlotinib and gefitinib in non-small cell lung cancer (NSCLC) [10, 11].